Marco Herling

Status: Laboratory PI, Senior Clinical Fellow
Address:

Clinic I of Internal Medicine
University Hospital Cologne
Kerpenerstr. 62
50937 Cologne

Phone: +49 221/478 5969
Fax: +49 221/478 88847
E-Mail: marco.herling@uk-koeln.de
Nationality: German

 

Education

1992 - 1999

Medical School, Martin-Luther-University (MLU), Halle-Wittenberg, Germany

1994 - 1999

Doctoral degree “Dr. med.”, Institute of Pathology, MLU

2002 - 2004

NIH Physician Scientist Training Program (curriculum for PhD in clinical research, mentor E.J. Freireich, MD), MDACC; Project and Thesis: “Bayesian statistics and novel trial designs in a proposal for T-PLL”

2005

Graduate Course (2 semester): The role of Physicians and Scientists in the Business World, Harvard Medical School, MIT Boston and MDACC

 

Professional and Research Experience

04/2000 - 04/2002

Clinical Resident / Fellow Internal Medicine, Department of Hematology / Oncology, University of Freiburg, Germany

04/2002 – 11/2006

Postdoctoral Fellow, Department of Hematopathology, MDACC, Laboratory of Dan Jones, MD PhD

12/2006 - present 

Senior Fellow, Department of Medicine I, Cologne University, Germany

12/2006 - present

Laboratory PI of “Lymphocyte signaling and oncoproteome”, Deutsche Krebshilfe Max-Eder junior group, Cologne University incl. CECAD

07/2010 - present

Adjunct Assistant Professor, Dept. of Hematopathology, MDACC

07/2013 -present

Co-founder and Scientific Board of DFG FOR1961 “Consortium for TCR-mediated Regulation and Oncogenesis in Lymphomas of T-cells; CONTROL-T”

 

Awards and Honours (selected)

1997-1998

Stipend by IALS - Biomedical Sciences Exchange Program (2-semester integrated Medical School curriculum at MDACC, Dept. of Lymphoma)

05/2004 - 11/2007

Odyssey Special Fellow Award, MDACC

06/2006 - 12/2010

Deutsche Forschungsgemeinschaft - Junior Investigator Award

08/2008 - 2015

Deutsche Krebshilfe Max-Eder Junior Group Award

 

Contributions to the Scientific Society

Ad hoc journal reviewer:
Blood; Leukemia; Br J Haematol; Eur J Hematol; Leuk Res; Int J Cancer, etc.

Appointed grant revisions: 
Leukaemia & Lymphoma Research (UK); FWF - Der Wissen-schaftsfonds (Austria); Association for International Cancer Research (UK)

Activity in editorial board:
Am J Hem Oncol (since 2004); Blood Cancer Journal (since 2010); American Journal of Blood Research (2011)

 

Professional Memberships

2002

American Society of Hematology (ASH)

2003

German Society of Hematology and Oncology (DGHO)

2004

American Society of Clinical Oncology (ASCO)

2010

German Society of Internal Medicine (DGIM)

2011

German Society of Medical Intensive Care and Acute Medicine (DGIIN)

2013

 Deutsche Gesellschaft für Ultraschall in der Medizin e.V. (DEGUM)

 

List of the five most important publications

  1. Prinz C, Vasyutina E, Lohmann G, Schrader A, Romanski S, Hirschhäuser C, Mayer P, Frias C, Herling CD, Hallek M, Schmalz HG, Prokop A, Mougiakakos D, Herling M. Organometallic nucleosides induce non-classical leukemic cell death that is mitochondrial-ROS dependent and facilitated by TCL1-oncogene burden. Mol Cancer. 2015 Jun 4;14(1):114.    

  2. Vasyutina E, Boucas JM, Bloehdorn J, Aszyk C, Crispatzu G, Stiefelhagen M, Breuer A, Mayer P, Lengerke C, Döhner H, Beutner D, Rosenwald A, Stilgenbauer S, Hallek M, Benner A, Herling M. The regulatory interaction of EVI1 with the TCL1A oncogene impacts cell survival and clinical outcome in CLL. Leukemia. 2015 Oct;29(10):2003-14.

  3. Fedorchenko O, Stiefelhagen M, Peer Zada AA, Barthel R, Mayer P, Eckei L, Breuer A, Crispatzu G, Rosen N, Landwehr T, Lilienthal N, Möllmann M, Montesinos-Rongen M, Heukamp L, Dürig J, Hallek M, Fingerle-Rowson G*, Herling M*. CD44 regulates the apoptotic response and promotes disease development in chronic lymphocytic leukemia. Blood 2013 May 16;121(20):4126-36 (* shared, order as published).

  4. Sivina M, Hartmann E, Vasyutina E, Boucas JM, Breuer A, Keating MJ, Wierda WG, Rosenwald A, Herling M*, Burger JA*. Stromal cells modulate TCL1 expression, interacting AP-1 components, and TCL1-targeting micro-RNAs in chronic lymphocytic leukemia. Leukemia 2012 Aug;26(8):1812-20, (* shared, order as published).

  5. Herling M, Patel KA, Weit N, Lilienthal N, Hallek M, Keating MJ, Jones D. High TCL1 levels are a marker of B-cell receptor pathway responsiveness and therapy resistance in chronic lymphocytic leukemia. Blood 2009 Nov 19;114(21):4675-86.

 

Patents and licensures:

  • anti-human TCL1 monoclonal mouse antibodies (non-exclusive licenses, MDACC)
  • therapeutic CCR4 chimeric antibodies (MDACC and Nagoya University, Japan)